Affilin® molecules are based on the human serum protein, Ubiquitin. They are generated by introducing new amino acids at defined positions on the surface of Ubiquitin. As up to 19 different amino acids are allowed in 8-14 positions, extremely diverse libraries are generated with a complexity of up to 1019 molecules.
Through this process, billions of different Affilin® molecules - all with unique binding characteristics - are obtained (Affilin® libraries). Next, well-established screening and selection technologies isolate Affilin® molecules specific for disease related targets. Primary hits are further optimized by proven maturation approaches. Throughout this process, valid biochemical and biological assays provide a detailed Affilin® characterization, reducing the risk of failure during drug development.
